Clinical Trials Browser

Phase 1/2 × OTHER × Bendamustine Hydrochloride × Clear all

NCT07225985 2026-03-06

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell

NCT05551936 2026-02-17

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

Phase 1/2 Active not recruiting

Lymphoma, Follicular

NCT05300282 2026-01-28

FIL_A-BEGEV

Phase 1/2 Recruiting

Hodgkin Disease, Recurrence

NCT04022239 2026-01-12

Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant

Phase 1/2 Recruiting

Hematopoietic and Lymphoid System Neoplasm

NCT03739619 2025-08-06

Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

Phase 1/2 Completed

3 enrolled 10 charts

Hodgkin Disease

NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Phase 1/2 Recruiting

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

NCT02002598 2024-09-19

Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma

Phase 1/2 Terminated

23 enrolled 13 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT01664910 2024-07-23

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Phase 1/2 Completed

27 enrolled 12 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT01754402 2024-02-20

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma

Phase 1/2 Unknown

56 enrolled 12 charts

Multiple Myeloma

NCT01177683 2023-10-06

Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

Phase 1/2 Terminated

32 enrolled 18 charts

Multiple Myeloma

NCT00951457 2022-03-03

Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01535924 2021-11-19

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase 1/2 Completed

26 enrolled 13 charts

Hodgkin Disease, Recurrence

NCT03259529 2021-06-07

BeGeRN

Phase 1/2 Completed

Lymphoma, Large B-Cell, Diffuse

NCT02059239 2021-02-21

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Phase 1/2 Completed

34 enrolled 22 charts

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT04762745 2021-02-21

The Efficacy and Safety of Pomalidomide and Bendamustine With Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Recurrence

NCT02799147 2020-11-23

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Phase 1/2 Completed

LymphoidOther hematologic neoplasm

Immune System Diseases, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02477215 2020-10-22

Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 1/2 Completed

38 enrolled 18 charts

Multiple Myeloma

NCT01657331 2020-07-17

SGN+Benda

Phase 1/2 Completed

Hodgkin Disease, Lymphoma, Large-Cell, Anaplastic

NCT03343652 2020-05-28

NB001

Phase 1/2 Completed

Hodgkin Disease

NCT01049945 2020-02-11

Bendamustine Hydrochloride, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1/2 Completed

70 enrolled 11 charts

Multiple Myeloma

NCT00916058 2019-06-04

Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma

Phase 1/2 Completed

57 enrolled 19 charts

Multiple Myeloma

NCT00987493 2019-05-15

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma

Phase 1/2 Completed

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT01165112 2018-12-05

TREC

Phase 1/2 Completed

48 enrolled 9 charts

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse

NCT01484626 2018-07-10

BVRD

Phase 1/2 Terminated

3 enrolled 4 charts

Multiple Myeloma

NCT00834678 2018-04-17

Bendamustine and Erlotinib in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Breast Cancer

Phase 1/2 Completed

11 enrolled 16 charts

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT00963534 2018-03-12

LENA-BERIT

Phase 1/2 Completed

Lymphoma, Mantle-Cell

NCT01078142 2017-09-11

BERT

Phase 1/2 Completed

Lymphoma, Follicular, Lymphoma, Mantle-Cell

NCT00856830 2017-07-17

Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer

Phase 1/2 Completed

30 enrolled 12 charts

Small Cell Lung Carcinoma

NCT00426855 2015-04-03

Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

Phase 1/2 Completed

12 enrolled 6 charts

Lymphoma, Lymphoma, Non-Hodgkin

NCT02134262 2014-11-06

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Phase 1/2 Unknown

Burkitt Lymphoma, Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

NCT00790855 2012-12-04

Bendamustine in Acute Leukemia and MDS

Phase 1/2 Terminated

27 enrolled 6 charts

LymphoidMyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01221103 2011-09-13

Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT01002703 2011-08-12

Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Unknown

Multiple Myeloma, Neoplasms, Plasma Cell